8-K: Mirum Pharmaceuticals Reports Strong 2023 Revenue Growth and Provides Business Update

Mirum Pharmaceuticals announced a 142% increase in total revenue for 2023, reaching $186.4 million, driven by strong sales of LIVMARLI and the integration of CHOLBAM and CHENODAL.

Summary

• Mirum Pharmaceuticals reported its financial results for the fourth quarter and year ended December 31, 2023, alongside a business update.
• The company's total revenue for 2023 reached $186.4 million, a 142% increase compared to $77.1 million in 2022.
• Net product sales for 2023 were $178.9 million, with LIVMARLI contributing $141.8 million, representing an 89% growth in LIVMARLI sales year-over-year.
• Mirum expects global net product sales of $310 million to $320 million in 2024.
• The company's operating expenses for 2023 totaled $293.0 million, up from $208.3 million in 2022, due to increased cost of goods sold and sales, general and administrative expenses.
• As of December 31, 2023, Mirum had $286.3 million in cash and cash equivalents.
• The PDUFA date for LIVMARLI in PFIC is on track for March 13, 2024.
• Interim analyses for the Volixibat VISTAS and VANTAGE studies are expected in the first half of 2024.
• A New Drug Application (NDA) for CHENODAL in CTX is planned for submission in the first half of 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, successful product integration, and promising pipeline developments. However, the increased operating expenses and net loss temper the overall optimism.

Positives

• Mirum achieved significant revenue growth in 2023, with a 142% increase year-over-year.
• LIVMARLI sales showed strong growth, increasing by 89% compared to the previous year.
• The company successfully integrated CHOLBAM and CHENODAL into its portfolio.
• Mirum has a strong cash position with $286.3 million in cash and cash equivalents.
• The PDUFA date for LIVMARLI in PFIC is on track for March 13, 2024.
• The company has multiple upcoming milestones in 2024, including regulatory submissions and interim study analyses.

Negatives

• Operating expenses increased significantly in 2023, reaching $293.0 million, compared to $208.3 million in 2022.
• The company reported a net loss of $160.9 million for the year ended December 31, 2023.
• The increase in operating expenses was primarily due to a $32.2 million increase in cost of goods sold and a $56.8 million increase in sales, general and administrative expenses.

Risks

• The financial information provided is unaudited and subject to change.
• Actual results may vary from the provided financial information.
• The company's future success depends on the continued commercial success of its approved products and the successful development and approval of its pipeline candidates.
• The company faces risks and uncertainties associated with its business, including geopolitical and macroeconomic events.

Future Outlook

Mirum expects continued revenue growth across all approved medicines in 2024, with global net product sales projected to be between $310 million and $320 million. The company also anticipates potential label expansions for LIVMARLI and CHENODAL, as well as interim analyses for volixibat adult indications.

Management Comments

• Chris Peetz, chief executive officer at Mirum, stated that 2023 was a landmark year for Mirum as they significantly expanded their commercial footprint and achieved strong global LIVMARLI growth.
• Chris Peetz also mentioned that they successfully integrated CHOLBAM and CHENODAL into their portfolio, strengthening their position as a leader in rare disease.
• Management is committed to their mission of delivering life changing medicines to patients in need.

Industry Context

Mirum's focus on rare diseases and its portfolio of approved medications positions it as a key player in the pediatric hepatology space. The company's growth trajectory and pipeline development align with the increasing attention and investment in rare disease therapeutics.

Comparison to Industry Standards

• Mirum's 142% revenue growth in 2023 is significantly higher than the average growth rate for pharmaceutical companies, especially those focused on rare diseases.
• Companies like Ultragenyx Pharmaceutical and BioMarin Pharmaceutical, which also focus on rare diseases, have shown strong revenue growth, but Mirum's growth rate is particularly impressive.
• The successful integration of CHOLBAM and CHENODAL into Mirum's portfolio is a positive sign, as it demonstrates the company's ability to expand its product offerings and market reach.
• The upcoming PDUFA date for LIVMARLI in PFIC is a critical milestone, as it could significantly expand the drug's market potential, similar to how Vertex Pharmaceuticals' Trikafta expanded the market for cystic fibrosis treatments.
• The interim analyses for Volixibat are also important, as they could provide data to support the drug's approval in additional indications, similar to how Intercept Pharmaceuticals' Ocaliva was approved for primary biliary cholangitis.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and positive outlook.
• Employees may be motivated by the company's success and growth prospects.
• Patients with rare diseases may benefit from the company's continued development of new treatments.
• Creditors may view the company's strong cash position favorably.

Next Steps

• Mirum will host a conference call on February 28, 2024, to discuss its financial results and provide business updates.
• The company is awaiting the PDUFA decision for LIVMARLI in PFIC on March 13, 2024.
• Mirum plans to submit a New Drug Application for CHENODAL in CTX in the first half of 2024.
• Interim analyses for the Volixibat VISTAS and VANTAGE studies are expected in the first half of 2024.

Key Dates

Keywords

Mirum Pharmaceuticals, LIVMARLI, Volixibat, CHENODAL, CHOLBAM, PFIC, CTX, Alagille syndrome, Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, Rare Diseases, Financial Results, Revenue Growth, PDUFA, NDA